18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: Newly identified lesions are more informative than standardized uptake value

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 530-537

  Bengtsson, Thomas ^a   Hicks, Rodney J ^b   Peterson, Amy ^a   Port, Ruediger E ^a  

^a GENENTECH INC   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

18F FDG PET; CT; NSCLC; Overall survival; Positron emission tomography; Survival modeling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TUMOR LEVEL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SURVIVAL TIME; TREATMENT DURATION; TUMOR VOLUME; CLINICAL TRIAL; DRUG RESISTANCE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; STATISTICAL MODEL; SURVIVAL; TIME; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIKELIHOOD FUNCTIONS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; QUINAZOLINES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84859397159     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092544     Document Type: Article

References (27)

1. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: the incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010;73:470-480.
2. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for pet response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
3. 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50(suppl 1):31S-42S.
4. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292. (Pubitemid 46606405)
5. 18F] fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol. 2006;24:3026-3031.
6. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets. 2010;10:433-461.
7. 18F-FDG PET. J Nucl Med. 2009;50(suppl 1):97S-105S.
8. Klein J, Moeschberger M. Survival Analysis. 2nd ed. New York, NY: Springer; 2003.
9. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons; 2002.
10. Claret L, Andre V, de Alwis D, Bruno R. Using change in tumor size as primary endpoint in oncology phase II studies. Available at: www.page-meeting.org/? abstract=1386. Accessed February 14, 2012.
11. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009;86:167-174.
12. Claret L, Girard P, Hoff PM, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009;27:4103-4108.
13. Binns D, Pirzkall A, Yu W, et al. OSI3926g Study Team. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:642-650.
14. Mileshkin LR, Hughes BG, Mitchell P, et al. Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E). Clin Cancer Res. 2011;17:3304-3315.
15. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol. 2011;29(suppl):7505.
16. Shankar L, Hoffman J, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059-1066. (Pubitemid 46939960)
17. Patel P, Bothos J, Fredrickson J, Bengtsson T, Peterson A, de Crespigny A. Results from FDG-PET imaging in OAM4558g, a randomized, placebo-controlled, multicenter phase II trial of erlotinib +/- metmab in second- and third-line NSCLC. Presented at the World Conference on Lung Cancer 2011; July 3-7, 2011; Amsterdam, The Netherlands.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pre- treatment fluorodeoxyglucose- positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 2010;116:5030-5037.
20. Hickeson M, Yun M, Matties A, et al. Use of a corrected standardized uptake value based on the lesion size on ct permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29:1328-1333.
21. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782. (Pubitemid 29512308)
22. Rosell R, Gervais R, Vergnenegre A. Erlotinib versus chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Tarceva versus Chemotherapy (EURTAC) phase III randomized trial [abstract]. J Clin Oncol. 2011;29(suppl):7503.
23. Berghmans T, DusartM, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6-12.
24. Um S, Kim H, Koh W, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2009;4:1331-1336.
25. Cox D. Regression models and life tables (with discussion). JR Stat Soc. 1972;34:187-220.
26. Cox D. Partial likelihood. Biometrika. 1975;62:269-276.
27. Bradburn M, Clark T, Love S, Altman D. Survival analysis part II: multivariate data analysis - an introduction to concepts and methods. Br J Cancer. 2003;89:431-436. (Pubitemid 37026422)